That is true. I have been speaking to a lot of funds that are large enough to be able to afford to have a biotech analysts, yet few do. When I get to talk to those that do have one, the quality of conversation is on another level - instead of talking about short term catalysts of the SP, I get into the nitty-gritty of our development and commercialisation strategy. These investors really get what we are trying to do and can see the value, not just can how they make a quick buck to boost their quarterly numbers.
RAC - Charts & Price Action, page-333
-
- There are more pages in this discussion • 21,196 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
